[1] ZHOU Q，YAO T W，ZENG S. The metabolic basis for rational prescription of drugs within the similar therapeutic or structural class[J] . Chin J Hosp Pharm (中国医院药学杂志)，2000，20 (10)：621-623. [2] ZHOU Q，YAO T W，ZENG S. Studies of metabolic drug interactions[J] . Chin J Clin Pharmacol(中国临床药理学杂志)，2001，17(4)：313-318. [3] ZHOU Q，WANG O M，YAN X F，et al. Comparison of drugs in our hospital between 1991 and 2001[J] . Chin J Med Appl Pharm (中国现代应用药学杂志)，2002，19(6)：511-513. [4] WILLIAMS D，FEELY J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors [J] . Clin Pharmacokinet，2002，41(5)：343-370. [5] HSU W C，CHEN W H，CHANG M T，et al. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin[J] . Clin Neuropharmacol，2002，25(5)：266-268. [6] NEUVONEN P J，KANTOLA T，KIVISTO K T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole[J] . Clin Pharmacol Ther，1998，63(3)：332-341. [7] MAZZU A L，LASSETER K C，SHAMBLEN E C，et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin[J] . Clin Pharmacol Ther，2000，68(4)：391-400. [8] BACKMAN J T，KYRKLAUND C，KIVISTO K T，et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil[J] . Clin Pharmacol Ther，2000，68(2)：122-129. [9] KANATHUR N，MATHAI M G，BYRD R P，et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis[J] . Tenn Med，2001，94(9)：339-341. [10] LEWIN J J，NAPPI J M，TAYLOR M H. Rhabdomyolysis with concurrent atorvastatin and diltiazem[J] . Ann Pharmacother，2002，36(10)：1546-1549. [11] KANTOLA T，KIVISTO K T，NEUVONEN P J. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations[J] . Clin Pharmacol Ther，1998，64(2)：177-182. [12] SIEDLIK P H，OLSON S C，YANG B B，et al. Erythromycin coadministration increases plasma atorvastatin concentrations[J] . J Clin Pharmacol，1999，39(5)：501-504. [13] SIMARD C，O'HARA G E，PREVOST J，et al. Study of the drug-drug interaction between simvastatin and cisapride in man[J] . Eur J Clin Pharmacol，2001，57(3)：229-234. [14] AMSDEN G W，KUYE O，WEI G C. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers[J] . J Clin Pharmacol，2002，42(4)：444-449. [15] LEE A J，MSDDIX D S. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin[J] . Ann Pharmacother，2001，35(1)：26-31. [16] CORSINI A，BELLOSTA S，BAETTA R，et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins[J] . Pharmacol Ther，1999，84(3)：413-428. [17] ASBERG A，HARTMANN A，FJELDSA E，et al. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients[J] . Am J Transplant，2001，1(4)：382-386. [18] FARMER J A，TORRE-AMIONE G. Comparative tolerability of the HMG-CoA reductase inhibitors[J] . Drug Saf，2000，23(3)：197-213. [19] NISHIO S，WATANABE H，KOSUGE K，et al. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension[J] . Hypertens Res，2005，28(3)：223-227. [20] ZENG S. Drug Metabolism(药物代谢学) [M] . Zhejiang：Zhejiang University Publishing House，2004：175-194. [21] LI Z D，SHI X J，WANG D Y，et al. Drug-induced rhabdomyolysis [J] . Chin J Clin Pharm (中国临床药学杂志)，2003，12(1)：54-58.